BPL-1357 Influenza Vaccine Trial Results Released
A Phase 1 clinical trial found the experimental BPL-1357 vaccine was well tolerated and induced immune responses.
Updated on Oct. 12, 2026 in Diseases — General
Live Poll
Does evidence of new vaccine efficacy increase your trust in future universal influenza protection?
Researchers have completed a Phase 1 clinical trial evaluating the safety and immunogenicity of the BPL-1357 influenza vaccine. The study involved 45 healthy participants and explored vaccine responses across multiple influenza strains.
Why it matters
Current influenza vaccines often provide limited protection against strains or subtypes not specifically included in the formulation. This trial explored a new candidate designed to address that limitation by testing broader immune responses.
In this Phase 1 clinical trial, 71.4% of participants showed an IgG response to H3 and H5 strains, while 85.7% responded to the H7 strain. Researchers measured these immune responses following a prime and boost vaccination schedule.
The players
BPL-1357
This is an experimental influenza vaccine candidate currently undergoing clinical investigation.
The details
The study administered doses through intramuscular and intranasal routes to determine safety and immunogenicity. Results indicated that adverse effects were primarily mild, and the vaccine successfully induced serum IgG titers against multiple influenza strains.
Timeline
Vaccine doses were administered using a prime and boost strategy 28 days apart.
The primary endpoint assessment for adverse events occurred 28 days after the boost.
Secondary endpoint assessments for adverse events were conducted 182 days after the boost.
The Big Picture
This study follows a pattern set by the clinical trial registration NCT05027932. The research marks a progression in the development of influenza vaccines designed to offer broader protection than seasonal shots.
This development represents early-stage scientific research and does not currently impact the availability or type of flu vaccines available to the public. Patients should continue to follow existing seasonal vaccination guidance from their healthcare providers.
The takeaway
While this Phase 1 trial shows promise regarding the safety and immune response of the BPL-1357 vaccine, it is only the first step in a long development process. Large-scale efficacy trials are still required before any new influenza vaccine can reach the public.
What happens next
Future studies will evaluate vaccine efficacy against influenza infection and disease, while researchers conduct further work to assess different dose levels and characterize induced immunity.
Further reading
Learn more about the latest research in Diseases — General.
More information
View the Clinical trial registration details for more on the study design.
Live Poll
Does evidence of new vaccine efficacy increase your trust in future universal influenza protection?
